血管性认知障碍发病机制及诊治研究进展

doi:10.3969/j.issn.1003-9198.2026.01.016

摘要/Abstract

摘要： 血管性认知障碍(VCI)是继阿尔茨海默病之后第二常见的认知障碍性疾病。随着人口老龄化进程加快,VCI的发病率不断上升,已成为重要的公共卫生问题。本文综述了VCI发病机制的最新研究进展,重点讨论了脑血管病变、神经血管单元功能紊乱、氧化应激和神经炎症等多重病理过程。同时介绍了VCI的诊断方法,主要包括临床症状评估、神经心理学测试和影像学检查。血管性认知障碍分类共识研究(VICCCS)标准提供了规范化的诊断框架。文章还探讨了药物治疗、非药物干预的研究进展,结合最新证据,提出了VCI的诊疗思路。

关键词: 血管性认知障碍, 脑血管病变, 神经血管单元, 治疗策略, 发病机制

Abstract: Vascular cognitive impairment (VCI) is the second most common cognitive disorder after Alzheimer’s disease. With the acceleration of population aging, the incidence of VCI continues to rise, becoming a significant public health concern. This review summarizes recent advances in understanding VCI pathogenesis, focusing on multiple pathological processes including cerebrovascular lesions, neurovascular unit dysfunction, oxidative stress, and neuroinflammation. The diagnostic methods of VCI are also introduced, which mainly include clinical symptom assessment, neuropsychological testing, and imaging examinations. The standard of Vascular Impairment of Cognition Classification Consensus Study (VICCCS) provides a standardized diagnostic framework. This article also discusses the research progress of drug therapy and non-drug intervention, and puts forward the diagnosis and treatment ideas of VCI based on the latest evidence.

Key words: vascular cognitive impairment, cerebrovascular lesions, neurovascular unit, treatment strategies, pathogenesis

中图分类号:

R 743

王一芳, 李婷婷, 吴晋. 血管性认知障碍发病机制及诊治研究进展[J]. 实用老年医学, 2026, 40(1): 78-82.

WANG Yifang, LI Tingting, WU Jin. Research progress on pathogenesis, diagnosis and treatment of vascular cognitive impairment[J]. Practical Geriatrics, 2026, 40(1): 78-82.

参考文献

[1] JIA L, DU Y, CHU L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020, 5(12): e661-e671.
[2] BATTLE C E, ABDUL-RAHIM A H, SHENKIN S D, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 2(2): CD013306.
[3] MOK V C T, CAI Y, MARKUS H S. Vascular cognitive impairment and dementia: mechanisms, treatment, and future directions[J]. Int J Stroke, 2024, 19(8): 838-856.
[4] BASAK J M, FALK M, MITCHELL D N, et al. Targeting BACE1-mediated production of amyloid beta improves hippocampal synaptic function in an experimental model of ischemic stroke[J]. J Cereb Blood Flow Metab, 2023, 43(2_suppl): 66-77.
[5] HU W J, WEI H, CAI L L, et al. Magnetic targeting enhances the neuroprotective function of human mesenchymal stem cell-derived iron oxide exosomes by delivering miR-1228-5p[J]. J Nanobiotechnology, 2024, 22(1): 665.
[6] BARATI A, MOGHIMI S, TAGHAVI ZANJANI K, et al. Acute administration of edaravone improves cognitive impairment in a mouse model of mPFC ischemia: crosstalk between necroptosis, neuroinflammation, and antioxidant defense[J]. Mol Neurobiol, 2025, 62(4): 4420-4434.
[7] OOMENS J E, VAN GILS V, VOS S J B, et al. Cerebral microbleeds and amyloid pathology estimates from the amyloid biomarker study[J]. JAMA Netw Open, 2025, 8(1): e2455571.
[8] CHEN J Y, YE Z X, WANG X F, et al. Nitric oxide bioavailability dysfunction involves in atherosclerosis[J]. Biomed Pharmacother, 2018, 97: 423-428.
[9] RAJEEV V, FANN D Y, DINH Q N, et al. Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment[J]. Theranostics, 2022, 12(4): 1639-1658.
[10] SWEENEY M D, SAGARE A P, ZLOKOVIC B V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol, 2018, 14(3): 133-150.
[11] FAN Y, LV X, CHEN Z, et al. m6A methylation: critical roles in aging and neurological diseases[J]. Front Mol Neurosci, 2023, 16: 1102147.
[12] KARA B, GORDON M N, GIFANI M, et al. Vascular and nonvascular mechanisms of cognitive impairment and dementia[J]. Clin Geriatr Med, 2023, 39(1): 109-122.
[13] WEAVER N A, KUIJF H J, ABEN H P, et al. Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts[J]. Lancet Neurol, 2021, 20(6): 448-459.
[14] COENEN M, DE KORT F A, WEAVER N A, et al. Strategic white matter hyperintensity locations associated with post-stroke cognitive impairment: a multicenter study in 1568 stroke patients[J]. Int J Stroke, 2024, 19(8): 916-924.
[15] FERNÁNDEZ-ANDÚJAR M, DOORNINK F, DACOSTA-AGUAYO R, et al. Remote thalamic microstructural abnormalities related to cognitive function in ischemic stroke patients[J]. Neuropsychology, 2014, 28(6): 984-996.
[16] RAJEEV V, FANN D Y, DINH Q N, et al. Intermittent fasting attenuates hallmark vascular and neuronal pathologies in a mouse model of vascular cognitive impairment[J]. Int J Biol Sci, 2022, 18(16): 6052-6067.
[17] LI J, LUO T, WANG X, et al. A heterozygous mutation in NOTCH₃ in a Chinese family with CADASIL[J]. Front Genet, 2022, 13: 943117.
[18] RATELADE J, KLUG N R, LOMBARDI D, et al. Reducing hypermuscularization of the transitional segment between arterioles and capillaries protects against spontaneous intracerebral hemorrhage[J]. Circulation, 2020, 141(25): 2078-2094.
[19] SCHAEFFER S, IADECOLA C. Revisiting the neurovascular unit[J]. Nat Neurosci, 2021, 24(9): 1198-1209.
[20] WEI W, MA D, GU L, et al. Epimedium flavonoids improve cerebral white matter lesions by inhibiting neuroinflammation and activating neurotrophic factor signal pathways in spontaneously hypertensive rats[J]. Int Immunopharmacol, 2024, 139: 112683.
[21] ZHU F, YAO J, FENG M, et al. Establishment and evaluation of a clinical prediction model for cognitive impairment in patients with cerebral small vessel disease[J]. BMC Neurosci, 2024, 25(1): 35.
[22] KIM S, NA H K, SUN Y, et al. Regional burden of enlarged perivascular spaces and cognition and neuropsychiatric symptoms in drug-naive patients with parkinson disease[J]. Neurology, 2024, 102(12): e209483.
[23] ANDRIUTA D, OTTOY J, RUTHIRAKUHAN M, et al. Perivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases[J]. Alzheimers Dement, 2024, 20(8): 5800-5808.
[24] KINJO Y, SAJI N, MUROTANI K, et al. Enlarged perivascular spaces are independently associated with high pulse wave velocity: a cross-sectional study[J]. J Alzheimers Dis, 2024, 101(2): 627-636.
[25] LIANG J, PAN Y, ZHANG W, et al. Associations between atherosclerosis and subsequent cognitive decline: a prospective cohort study[J]. J Am Heart Assoc, 2024, 13(21): e036696.
[26] BERAN M, JANSEN W J, OOMENS J E, et al. Biomarkers of endothelial dysfunction and cognition: a two-step IPD meta-analysis[J]. Alzheimers Dement, 2024, 20(12): 8402-8411.
[27] COENEN M, BIESSELS G J, DECARLI C, et al. Spatial distributions of white matter hyperintensities on brain MRI: a pooled analysis of individual participant data from 11 memory clinic cohorts[J]. Neuroimage Clin, 2023, 40: 103547.
[28] MA J, LIU F, WANG Y, et al. Frequency-dependent white-matter functional network changes associated with cognitive deficits in subcortical vascular cognitive impairment[J]. Neuroimage Clin, 2022, 36: 103245.
[29] JIANG D, LIN Z, LIU P, et al. Brain oxygen extraction is differentially altered by Alzheimer’s and vascular diseases[J]. J Magn Reson Imaging, 2020, 52(6): 1829-1837.
[30] ENGSTROM A C, ALITIN J P M, KAPOOR A, et al. Spontaneous cerebrovascular reactivity at rest in older adults with and without mild cognitive impairment and memory deficits[J]. Alzheimers Dement, 2025, 21(1): e14396.
[31] AREOSA S A, SHERRIFF F, MCSHANE R. Memantine for dementia[J]. Cochrane Database Syst Rev, 2005(3): Cd003154.
[32] COTRONEO A M, CASTAGNA A, PUTIGNANO S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study[J]. Clin Interv Aging, 2013, 8: 131-137.
[33] ALVAREZ-SABÍN J, ORTEGA G, JACAS C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment[J]. Cerebrovasc Dis, 2013, 35(2): 146-154.